Table 6_The efficacy and safety of colistimethate sodium in the treatment of carbapenem-re

Tingyuan Zhang's prospective observational study evaluates colistimethate sodium for treating carbapenem-resistant Gram-negative bacilli infections. The dataset includes results from 222 patients aged ≥14 years across nine ICUs in Henan Province, China, collected between November 2021 and November 2023. It reports clinical response rates, 30-day mortality, and adverse events including acute kidney injury.

Use Cases

• Modeling risk factors for poor clinical response based on APACHE II scores, infection site, and microbial composition.
• Analyzing the incidence and severity of drug-associated acute kidney injury based on baseline serum creatinine levels.
• Comparing clinical and microbiological response rates between patients with single-site versus multi-site infections.
• Evaluating 30-day all-cause mortality predictors in ICU patients receiving colistimethate sodium.

Strengths

• Data is from a prospective, observational study described as the first of its kind in China.
• Includes specific outcome metrics: 82.5% overall clinical response rate and 19.8% 30-day all-cause mortality.
• Reports subgroup analyses for infection site and microbial type, and multivariable regression results for risk factors.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• Data is limited to 222 patients from nine ICUs in a single Chinese province, which may limit generalizability.
• The primary data file is a 13.1 KB DOCX document, suggesting the underlying dataset is very small in scale.

Provenance

Source

Tingyuan Zhang via figshare.

Collection Method

Prospective observational study of consecutively enrolled patients in nine ICUs.

Time Range

November 2021 to November 2023.

Freshness

Last updated 2026-05-29 04:45:27; freshness should be verified.

Geography

Henan Province, China.